50 results on '"Mansfield, A.S."'
Search Results
2. P2.16-03 RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer
3. EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma
4. MA17.10 miRNA Signatures In Mesothelioma and their Associations with Outcomes with Immune Checkpoint Inhibitors
5. EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression
6. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
7. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer
8. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
9. Nivolumab (NIVO) plus ipilimumab (IPI) vs chimiothérapie (chimio) en traitement de première ligne du mésothéliome pleural malin (MPM) non résécable : résultats à 4 ans de l’étude CheckMate 743
10. 125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (“PAVE”) in advanced non-small cell lung cancer (NSCLC) patients (pts)
11. 139P The timing, dynamics, and co-occurrence of immune-related adverse events with a PD-L1 inhibitor in non-small cell lung cancer
12. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
13. EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
14. 1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
15. LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
16. 1175P Predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated on the Pacific regimen
17. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
18. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
19. LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
20. 17P Effects of tumour mutation burden on the antigen presentation pathway
21. 1482O - Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
22. 442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
23. Adjuvant Radiation Therapy for Pleural Mesothelioma after Extrapleural Pneumonectomy (EPP) or Pleurectomy and Decortication (P+D)
24. 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
25. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
26. 84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups
27. 1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
28. 1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours
29. Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
30. IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
31. Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas
32. Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice
33. Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center
34. Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed Stereotactic Body Radiation Therapy
35. OA02.04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630.
36. 1736O - IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
37. Pulmonary sarcomatoid carcinoma—a new hope
38. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer
39. IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
40. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply
41. Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
42. 88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer
43. 70 Heterogeneity of programmed death-ligand 1 expression in multifocal lung cancer
44. 115 Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer
45. Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials
46. Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis
47. CD11ahighCD8+ T Cell Phenotype Identifies Tumor Specific Effector Cells Whose Frequency and Function Are Enhanced by RT
48. Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer
49. 58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
50. Ablative Radiotherapy for Ultracentral Primary Non-Small Cell Lung Cancer: Dosimetric and Anatomic Predictors of Outcomes and Toxicities.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.